Evidence map›Paper›PMID 40641963›Full record

SynthesisFrontiers in medicine2025

Non-invasive biomarkers to diagnose and monitor eosinophilic esophagitis: a systematic review.

Sophia-Louise Noble, Richard Tyrrell, Thomas C Mules, Stephen Inns

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Shifting the scope: Moving toward less invasive diagnosis and monitoring of eosinophilic esophagitis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sophia-Louise NobleMalaghan Institute of Medical Research, Wellington, New Zealand.
Richard TyrrellDepartment of Medicine, University of Otago, Wellington, New Zealand.
Thomas C MulesMalaghan Institute of Medical Research, Wellington, New Zealand.
Stephen InnsDepartment of Medicine, University of Otago, Wellington, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Current assessments for diagnosing and monitoring eosinophilic esophagitis (EoE) are invasive, time-intensive and costly. The development of non-invasive biomarkers that are sensitive and specific for EoE is paramount. We aimed to provide a comprehensive update on the latest biomarker discovery research in EoE and discuss the current state of the field. Methods: PubMed, Web of Science, Medline and Embase were searched for studies on non-invasive biomarkers for EoE. Extracted studies were analyzed for risk of bias and relevant data was extracted, including study design, participants, information on controls, biomarker detection method, biomarkers studied, and biomarkers for which statistical significance was found. Results: Of the 239 studies identified, 37 articles met the inclusion criteria and were included in the systematic review. Across these studies, over 80 biomarkers were evaluated as potential non-invasive tools for diagnosing and monitoring EoE. While the most commonly investigated biomarker was peripheral eosinophil count (PEC), overall PEC demonstrated limited reliability. Other emerging biomarkers, including eosinophil-derived proteins (e.g., EDN, MBP-1) and cytokines (e.g., eotaxin-3), showed promise, although findings were inconsistent between studies. Esophageal-specific sampling methods, such as the Cytosponge, esophageal string test (EST), and esophageal brushings, demonstrated strong correlations with histologic eosinophil counts and disease activity, particularly through the measurement of eosinophil-associated proteins. Conclusion: Esophageal-specific sampling methods show significant promise for accurately diagnosing and monitoring EoE, particularly through eosinophil-derived biomarkers, such as eosinophil-derived neurotoxin (EDN). Furthermore, these methods were better tolerated and more cost-effective compared to endoscopy and biopsy.

Indexed as

biomarkersdiagnosisdisease monitoringeosinophilic esophagitisnon-invasive biomarkers

Identifiers

PMID40641963
PMCPMC12240998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.